TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11165880
Drug: Parenteral Nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral Nutrition (TPN)
Study: 10322244
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg
Study: 31097971
Drug: Tian Jiu
Normalized name: Tian Qi Root
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tian Jiu (TJ) therapy
Study: 19499846
Drug: rifaximin 1200
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rifaximin 1200 mg/day
Study: 20633511
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injections
Study: 21285531
Drug: All vaccines
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All vaccines (including both adjuvanted and non-adjuvanted)
Study: 29125901
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 400 mg once a day
Study: 31344386
Drug: Vehicle treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle treatment (control)
Study: 29843492
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg daily clopidogrel or triple therapy with clopidogrel and cilostazol
Study: 24711073
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg PHGG daily for 4 weeks
Study: 16317669
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 1 g/day for three weeks
Study: 16317669
Drug: Dexamethasone 12
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 12 mg/day for 1 week and placebo during weeks 2 and 3
Study: 17362495
Drug: Immediate restoration
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate restoration with tapered, roughened-surface Southern implants, provisional screw-retained crowns placed within 4 hours of implant placement, and definitive crowns placed 8 weeks later
Study: 3935313
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (5 mg delivered over 24 hours, applied every 48 hours)
Study: 11054989
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin
Study: 12390596
Drug: Doxycycline monohydrate
Normalized name: Doxycycline Monohydrate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline monohydrate 100 mg daily tablet
Study: 8803666
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate (specific dosing strategies not detailed)
Study: 30967589
Drug: Animal-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-assisted therapy (AAT)
Study: 30888024
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for tuberculosis
Study: 2139769
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate 20 mg/day during the luteal phase
Study: 26261902
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of IAA or baseline insulin use
Study: 12003381
Drug: Alcohol injection
Normalized name: Dehydrated Alcohol Injection Solution
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol injection
Study: 11504270
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intravenous [14C]omapatrilat
Study: 27481017
Drug: Simethicone administration
Normalized name: Simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone administration
Study: 16377065
Drug: 5 x
Normalized name: PAD,ABDOMINAL 5 X 9 STERILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 x 250 mg progesterone
Study: 30222962
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid (25 mg)
Study: 24261644
Drug: Intravenous haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous haloperidol 1 mg/q8h
Study: 28800090
Drug: Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Bicarbonate (1680 mg)
Study: 20070744
Drug: Implant placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant placed in extraction socket
Study: 8643858
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (baseline treatment only, fluconazole given only when mycotic infections appeared)
Study: 12468601
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil (40 g fat)
Study: 12468601
Drug: No-fat test
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-fat test meal (0 g fat)
Study: 31719214
Drug: Bacillus subtilis
Normalized name: Bacillus Subtilis
DrugBank: Bacillus subtilis (DB11347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus subtilis MB40 at 5 × 10^9 CFU once daily for 4 weeks
Study: 8217179
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam 0.03 mg/kg
Study: 10635302
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (UFT 300‐450 mg/day, 5 days a week and 5‐FU 440‐600 mg/m2/24 hr once a week)
Study: 6093656
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active drug intervention
Study: 18991816
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with target levels of glycemia (n=41)
Study: 31250285
Drug: rTMS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTMS treatment
Study: 75438
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (egg and cows' milk preparation)
Study: 8628543
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% administered twice daily
Study: 19517895
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg tablets of the originator product (reference formulation)
Study: 17604592
Drug: Gabapentin adjuvant
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin adjuvant to ongoing opioid treatment (group GO)
Study: 17200266
Drug: Pentavalent rotavirus
Normalized name: Vaccine product containing only live pentavalent Rotavirus antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent rotavirus vaccine (3 oral doses at approximately 1.1 x 10(7) infectious U per dose)
Study: 10835440
Drug: 2 mg/h
Normalized name: nicotine 0.312 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/h nimodipine (high-dose)
Study: 20605555
Drug: Ischemic compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ischemic compression therapy on cervical and upper thoracic areas (control group)
Study: 20605555
Drug: Ischemic compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ischemic compression therapy on shoulder trigger points (after crossover for control group)
Study: 12956257
Drug: Travoprost 0.004%
Normalized name: TRAVOPROST 0.004% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travoprost 0.004% once daily
Study: 20605555
Drug: Ischemic compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ischemic compression therapy on shoulder trigger points
Study: 27875516
Drug: 12 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months of trastuzumab treatment
Study: 26488759
Drug: Hypnotic induction
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic induction
Study: 27215502
Drug: Glycopyrrolate (GLY)
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (GLY) 15.6 μg twice daily (b.i.d.)
Study: 18342647
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive (COC)
Study: 26025796
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravenous propacetamol
Study: 12120185
Drug: Tegaserod 6
Normalized name: tegaserod 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 6 mg twice daily
Study: 11783602
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (3 daily injections of regular insulin and 1 or 2 daily injections of intermediate acting insulin associated with metformin 500 mg twice daily in 64% of patients) in Group B (a) to achieve HbA1c < 7.5%.
Study: 16458133
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/day
Study: 14523770
Drug: Vaccine
Normalized name: VACCINES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine
Study: 23672977
Drug: Single priming
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single priming dose of NeisVac-C® vaccine at 4 or 6 months of age
Study: 23672977
Drug: Single priming
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single priming dose of NeisVac-C® vaccine at 4 months
Study: 15374846
Drug: Inhaled triamcinolone
Normalized name: triamcinolone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled triamcinolone acetonide, 600 mcg, twice daily
Study: 17446206
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg atomoxetine
Study: 9469215
Drug: Nortriptyline (NT)
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nortriptyline (NT) treatment
Study: 8435990
Drug: Ethanol 0.5
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.5 g kg‐1 by intravenous bolus followed by 0.25 g kg‐1 h‐1
Study: 29764270
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of ethanol (blood alcohol level=80 mg%)
Study: 22224244
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (basic treatment without neuroprotectors)
Study: 26952945
Drug: Fosaprepitant 150
Normalized name: fosaprepitant 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant 150 mg intravenously in combination with palonosetron 0.25 mg intravenously and dexamethasone 16 mg orally.
Study: 26916172
Drug: 52-mg levonorgestrel
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 52-mg levonorgestrel (LNG-IUD)
Study: 15718316
Drug: External-beam radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: External-beam radiation therapy (EBRT) alone
Study: 7734257
Drug: Morphine 20
Normalized name: morphine 20 mg/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 20 mg administered before operation
Study: 3517560
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg BAY m1099
Study: 20067988
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose aprotinin (75,000 KIU/kg intra- and postoperatively)
Study: 11792161
Drug: Acute treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute treatment with levetiracetam (500 mg twice daily)
Study: 2027271
Drug: Enteric-coated calcium
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated calcium carbonate (3.6 g/d)
Study: 21042875
Drug: Krill oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill oil (N = 36; 3.0 g/day, EPA + DHA = 543 mg)
Study: 12409588
Drug: Low-dose spiral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose spiral computed tomography (CT)
Study: 9861520
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg daily
Study: 9028151
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (1200 mg/day)
Study: 23369221
Drug: Intensity-Modulated Radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensity-Modulated Radiation Therapy (IMRT)
Study: 24356636
Drug: Dose-dense weekly
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose-dense weekly paclitaxel and carboplatin (dd-TC)
Study: 9663829
Drug: Pentasa 1
Normalized name: Pentasa 10 MG/ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentasa 1 g suppository once daily
Study: 17396618
Drug: Pranlukast 450
Normalized name: pranlukast
DrugBank: Pranlukast (DB01411)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Pranlukast 450 mg daily
Study: 8718542
Drug: Estriol (E3)
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol (E3) 2 mg/day + Calcium lactate (Ca) 2 g/day (Group-E3 + Ca)
Study: 18004123
Drug: Haloperidol 5
Normalized name: haloperidol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 5 mg/d
Study: 26216195
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (32.2 g pre- and post-rehabilitation for two weeks)
Study: 24531027
Drug: Tube shunt
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tube shunt (350 mm² Baerveldt glaucoma implant)
Study: 24531027
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with mitomycin C (0.4 mg/mL for 4 minutes)
Study: 25635704
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT screening
Study: 23490092
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir (ETV) treatment group, n=35
Study: 3250183
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) oral tablets
Study: 10942856
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg sublingual buprenorphine (BUP)
Study: 27218476
Drug: Low concentration
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentration EtOH (targeted BrAC = 0.040 g/dl)
Study: 1352868
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid derivative (bis-hemisuccinate bisodic salt) at a dose of 600 mg/day for 6 months
Study: 6376317
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy utilizing MOPP chemotherapy
Study: 26874511
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of valsartan (regular-dose group)
Study: 27039236
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 320 μg via pMDI
Study: 19543129
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg
Study: 27039236
Drug: Formoterol (FM)
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol (FM) 9 μg via dry-powder inhaler
Study: 18523036
Drug: Difflam throat
Normalized name: Sucrets Sore Throat
DrugBank: Dyclonine (DB00645)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Difflam throat spray
Study: 26622463
Drug: Three 20-min
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 20-min doses of infrared radiation without 5-ALA once a week for 3 weeks
Study: 14656777
Drug: Rofecoxib (ROF)
DrugBank: Rofecoxib (DB00533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rofecoxib (ROF) 50 mg
Study: 15744240
Drug: PCV7 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV7 vaccine after autoHCT
Study: 17299612
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with interferon‐alpha (IFN‐alpha)‐2b (three million units, daily for eight weeks followed by three million units, three times a week for a further 16 to 40 weeks) and daily ribavirin (1.0 g to 1.2 g according to weight for 24 to 48 weeks)
Study: 10370734
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of uni- or bilateral internal mammary artery(ies) with saphenous vein grafts
Study: 7929727
Drug: Out-patient management
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Out-patient management with early, ultrasound-guided trans-abdominal paracentesis, intravenous hydration, fluid removal of 1-3 liters over 2-3 hours.
Study: 20106824
Drug: Combined ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined ramipril at 5 mg/day and valsartan at 80 mg/day
Study: 15512177
Drug: Danazol 200
Normalized name: danazol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol 200 mg daily
Study: 16384760
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (800 mg 5 times daily)
Study: 28476288
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg daily (blinded phase)
Study: 17520467
Drug: Azithromycin, 500
Normalized name: Azithromycin, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, 500 mg weekly for 12 weeks
Study: 15074089
Drug: Jingling oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jingling oral liquid (JLOL)
Study: 22990217
Drug: 2-mg nicotine
Normalized name: nicotine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mg nicotine gum
Study: 11331640
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate (3.6 mg/month for 6 months)
Study: 11331640
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA; 30 mg/day for 6 months)
Study: 9013162
Drug: Low-dose midazolam
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose midazolam (35 micrograms/kg) and pethidine (700 micrograms/kg in 48 patients, 500 micrograms/kg in 102 patients)
Study: 29558756
Drug: Network consulting
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Network consulting room management (video, voice, text, electronic prescriptions)
Study: 21044166
Drug: Implant-implant group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-implant group (2 adjacent implants)
Study: 19165648
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg twice daily
Study: 19739431
Drug: Ciclesonide hydrofluoroalkane
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide hydrofluoroalkane nasal aerosol (all doses)
Study: 9793615
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg naftidrofuryl (Praxilene)
Study: 24728329
Drug: Subcutaneous methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous methotrexate (SC MTX)
Study: 26233827
Drug: Nicotine administration
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine administration
Study: 1735336
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg loperamide oxide
Study: 25553511
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray during luteal phase
Study: 18436114
Drug: Darapladib 80
Normalized name: Darapladib
DrugBank: Darapladib (DB06311)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darapladib 80 mg
Study: 31690561
Drug: Stand alone
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stand alone VR (six week, internet based intervention with weekly online sessions and daily exercises)